Studies suggest CBD may possess the following medical properties:
|Medical Properties of CBD||Effects|
|Antiemetic||Reduces nausea and vomiting|
|Anticonvulsant||Suppresses seizure activity|
|Antipsychotic||Combats psychosis disorders|
|Anti-inflammatory||Combats inflammatory disorders|
|Anti-oxidant||Combats neurodegenerative disorders|
|Anti-tumoral/Anti-cancer||Combats tumor and cancer cells|
|Anxiolytic/Anti-depressant||Combats anxiety and depression disorders|
CBD seems to have many of the same medicinal uses as THC. However, CBD has drawn more interest due to its lack of psychoactive effects.
Most research on CBD has been conducted in animals, which makes it difficult to know how CBD works in human patients. However, CBD is currently being studied in patients with epilepsy and schizophrenia.
A pharmaceutical form of CBD called Epidiolex was recently developed for research by GW Pharmaceuticals. The company also makes the cannabis-based spray Sativex.
Hampson AJ, Grimaldi M, Axelrod J, Wink D (1998), Cannabidiol and (−)Δ9-tetrahydrocannabinol are neuroprotective antioxidants. Proceedings of the National Academy of Sciences 95: 8268–73.
Mechoulam, R., Parker, L. A. and Gallily, R. (2002), Cannabidiol: An Overview of Some Pharmacological Aspects. Journal of Clinical Pharmacology, 42: 11S–19S. doi: 10.1002/j.1552-4604.2002.tb05998.x
Pertwee RG (2008), The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: Δ9-tetrahydrocannabinol, cannabidiol and Δ9-tetrahydrocannabivarin. Br J Pharmacol, 153:199–215. doi: 10.1038/sj.bjp.0707442
Zanelati, T., Biojone, C., Moreira, F., Guimarães, F. and Joca, S. (2010), Antidepressant-like effects of cannabidiol in mice: possible involvement of 5-HT1A receptors. British Journal of Pharmacology, 159: 122–128. doi: 10.1111/j.1476-5381.2009.00521.x